Shares of Arcus Biosciences Inc (NYSE:RCUS) rose 3.4% on Wednesday following the launch of analyst coverage by TD Cowen, which initiated the stock with a Buy recommendation.
TD Cowen analyst Tara Bancroft began coverage of Arcus, highlighting the company’s lead investigational therapy casdatifan. In Bancroft’s view, casdatifan could emerge as the preferred HIF-2α inhibitor in renal cell carcinoma based on its target engagement characteristics relative to the competing drug Welireg and observed progression-free survival (PFS) data.
Bancroft noted that casdatifan’s reported median PFS of 15.1 months compares to Welireg’s 5.6 months. The analyst outlined a set of clinical outcomes that, if achieved by October, would materially reduce the risk associated with Phase III development and support broader adoption of casdatifan across treatment settings.
Specifically, Bancroft identified three clinical signals that would derisk Phase III trials: a 15-month median PFS for casdatifan administered with cabozantinib in a second-line setting; a primary progression rate below 20-30% for first-line treatment combining casdatifan with zimberelimab, with or without ipilimumab; and a signal indicating an overall survival benefit for casdatifan when given as monotherapy. Achieving these outcomes would, in the analyst’s assessment, enable casdatifan to compete across every line of therapy within the renal cell carcinoma market, which Bancroft values at more than $10 billion.
The analyst’s initiation of coverage signals optimism about Arcus Biosciences’ oncology pipeline, with renal cell carcinoma treatment prospects forming the central focus of the thesis.
Market reaction: The reported 3.4% intraday increase followed the publication of TD Cowen’s Buy rating and the accompanying clinical rationale provided by Bancroft.
Clinical benchmarks: The coverage initiation ties future derisking of Phase III programs to concrete clinical thresholds involving progression-free survival, primary progression rates in first-line combinations, and signals for overall survival.
Outlook: Bancroft’s commentary frames casdatifan as a potential multi-line therapy within a $10 billion-plus renal cell carcinoma market if the specified clinical signals materialize.